What is Ascletis Pharma testing in its new US Phase II trial?

Ascletis Pharma is testing ASC30, an oral small molecule GLP-1 receptor agonist, in a Phase II trial for the treatment of type 2 diabetes mellitus.

When will Ascletis Pharma release data from the ASC30 Phase II diabetes trial?

Ascletis Pharma expects to release top-line data from the 13-week Phase II study in the third quarter of 2026.

What is ASC30 and how can it be administered?

ASC30 is a small molecule GLP-1 receptor agonist that can be administered either once daily orally or via subcutaneous injection once monthly to quarterly for metabolic diseases like diabetes and obesity.

Home / Health / Ascletis Advances Oral GLP-1 Agonist for Diabetes

Ascletis Advances Oral GLP-1 Agonist for Diabetes

27 Jan

•

Summary

First participants dosed in US Phase II trial for type 2 diabetes.
Top line data expected in Q3 2026 for the 13-week study.
ASC30 is an oral small molecule GLP-1 receptor agonist.

Ascletis Advances Oral GLP-1 Agonist for Diabetes

Ascletis Pharma has commenced a Phase II clinical trial in the United States for ASC30, an oral small molecule designed to activate the glucagon-like peptide-1 (GLP-1) receptor. This new study focuses on treating type 2 diabetes mellitus. Approximately 100 participants will be enrolled across various US sites for this 13-week, double-blind, randomized, multi-center, and placebo-controlled trial.

The primary objective is to evaluate the safety, tolerability, and efficacy of ASC30 tablets. Key metrics will include the mean change in glycated hemoglobin (HbA1c) from baseline at week 13, compared to a placebo. Secondary endpoints encompass changes in fasting blood glucose and body weight, alongside overall safety assessments.

Ascletis anticipates releasing top-line data from this diabetes-focused Phase II study in the third quarter of 2026. The company previously conducted a similar 13-week Phase II trial of ASC30 for obesity, involving 125 overweight participants with related comorbidities.